Stay updated on Long-term Safety of SAGE-324 in Essential Tremor Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of SAGE-324 in Essential Tremor Clinical Trial page.

Latest updates to the Long-term Safety of SAGE-324 in Essential Tremor Clinical Trial page
- Check4 days agoChange DetectedRevision bumped from v3.0.1 to v3.0.2 and a Back to Top link was removed; core content remains unchanged.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has undergone significant changes in its location details, with the addition of a specific facility name and a more precise location in West Falls Church, Virginia, while removing previous location terms and references.SummaryDifference0.8%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe page has been updated to reflect the latest version, v2.16.11, replacing the previous version v2.16.10. Additionally, the estimated timestamps for 'Results First Posted' and 'Last Update Posted' have been removed.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has updated the study's location details, now listing 38 sites including Cincinnati, Ohio, and Orlando, Florida, while removing Winter Park, Florida, and Fairfax, Virginia. Additionally, the dosing schedule for the investigational product SAGE-324 has been clarified, detailing a titration from 15 mg to 60 mg over the treatment period.SummaryDifference41%
Stay in the know with updates to Long-term Safety of SAGE-324 in Essential Tremor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of SAGE-324 in Essential Tremor Clinical Trial page.